37 completed, 16 unknown, 10 withdrawn, 8 not yet recruiting. 94 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 94 | Completed 37, Unknown 16, Withdrawn 10, Not yet recruiting 8, Terminated 8, Recruiting 7, Active not recruiting 6, Enrolling by invitation 1, Suspended 1 |
Follow Adnexal Diseases: new trials by email Literature Review of Adnexal Diseases trials Research Report on Adnexal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| NK521 in the Treatment of Advanced Solid Tumors NK521 Cell Injection - Hepatocellular Carcinoma (HCC), Ovarian Cancer | Early Phase 1 | Not yet recruiting | Base Therapeutics (Shanghai) Co., Ltd. | 18 | 2027-01-01 | 2026-09-30 |
| Effect and Mechanism of Jiajian Guishen Optimized Formula on Premature Ovarian Insufficiency: Insights Into m6A Modification and Oxidative Stress JJGS - Premature Ovarian Insufficiency | Early Phase 1 | Not yet recruiting | Shi Yun | 45 | 2026-09-30 | 2026-09-25 |
| 89Zr-DFO-Mirvetuximab PET/CT Imaging for Companion Diagnosis and Response Evaluation in Ovarian Cancer 89Zr-DFO-Mirvetuximab PET/CT - Epithelial Ovarian Cancer, Ovarian Cancer | Early Phase 1 | Not yet recruiting | Peking University Cancer Hospital & Institute | 20 | 2026-09-01 | 2026-08-27 |
| Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer [64Cu]CM500, [68Ga]CM500, PET/MR - Bladder Cancer, Glioma | Early Phase 1 | Not yet recruiting | Lumina Pharmaceuticals Inc | 40 | 2026-09-01 | 2026-08-28 |
| Opportunistic Salpingectomy During Bariatric Surgery for Ovarian Cancer Prevention Opportunistic salpingectomy at time of bariatric surgery - Ovarian Cancer, Bariatric Surgery | Early Phase 1 | Not yet recruiting | St. Joseph's Healthcare Hamilton | 66 | 2026-08-01 | 2026-08-12 |
| An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors. KT032(anti-MSLN chimeric antigen receptor autologous T cell injection) - Ovarian Cancer, Mesothelioma | Early Phase 1 | Not yet recruiting | Weijia Fang, MD | 24 | 2026-03-15 | 2026-02-19 |
| Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy Biospecimen Collection, Placebo Administration, Probiotic - Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 161 | 2026-03-06 | 2026-08-17 |
| Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome red yeast rice，RYR - Polycystic Ovary Syndrome (PCOS) | Early Phase 1 | Recruiting | Sichuan Provincial People's Hospital | 90 | 2025-07-28 | 2025-08-06 |
| Lipid Mediators & Cancer: Montelukast, SPM, and Almonds No Interventions, Sports Pro Resolve 4 g, Double Wood SPM 4 g - Colorectal Cancer, Sarcoma | Early Phase 1 | Not yet recruiting | University of South Florida | 56 | 2025-03-01 | 2025-03-20 |
| The Influence of Gut Microbiota on Ovarian Function: A Single-center, Randomized,Double Blind, Parallel-controlled, Exploratory Clinical Trial Akk Gut Bacteria Supplement, Give a placebo - Premature Ovarian Failure (POF) | Early Phase 1 | Active not recruiting | Songling Zhang | 60 | 2025-03-01 | 2025-12-29 |
| Allogeneic B7H3 CAR-γδT Cell Therapy for Advanced Solid Tumors Fludarabine, Cyclophosphamide, B7H3 CAR-γδT cells - Advanced Solid Tumors, Ovarian Cancers | Early Phase 1 | Not yet recruiting | Peking University | 18 | 2025-03-01 | 2025-02-13 |
| Clinical Trial of Anovulatory Infertility a compound prescription of Chinese medicine - Polycystic Ovary Syndrome, Diminished Ovarian Reserve | Early Phase 1 | Enrolling by invitation | Affiliated Hospital of Nanjing University of Chinese Medicine | 650 | 2024-09-30 | 2025-02-11 |
| Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Ovarian Epithelial Carcinoma SZ011 CAR-NK - Ovarian Epithelial Carcinoma | Early Phase 1 | Unknown | Shantou University Medical College | 12 | 2024-08-13 | 2024-08-13 |
| Sub-therapeutic GnRH- Antagonist Treatment to Rectify LH Pulsatility in Lean Women With PCOS. Ganirelix - Polycystic Ovary Syndrome | Early Phase 1 | Completed | University Hospital, Lille | 20 | 2024-04-17 | 2025-04-27 |
| ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer Wee1 Inhibitor ZN-c3 - Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-07-30 | 2023-05-06 | |
| Effect and Mechanism of Jiajian Guishen Formulation on Premature Ovarian Insufficiency Based on Metabolomics Jiajian Guishen Formulation - Premature Ovarian Insufficiency, Metabolomics | Early Phase 1 | Completed | Shi Yun | 46 | 2023-07-24 | 2024-12-05 |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors Recombinant oncolytic herpes simplex virus type 1 (R130) - Lung Cancer, Bronchial Cancer | Early Phase 1 | Unknown | Shanghai Yunying Medical Technology | 24 | 2023-03-30 | 2023-06-02 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer Recombinant oncolytic herpes simplex virus type 1 (R130) - Ovarian Cancer, Peritoneal Carcinomatosis | Early Phase 1 | Unknown | Shanghai Yunying Medical Technology | 10 | 2022-12-02 | 2023-04-06 |
| A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in Patients With Advanced Cancer MB1707 - Advanced Solid Tumor, Breast Cancer | Early Phase 1 | Withdrawn | Mainline Biosciences, Inc. | 2022-12-01 | 2023-12-21 |
Showing 20 of 94. Sign in to see all of them.
Ovarian Neoplasms (49) · Polycystic Ovary Syndrome (27) · Fallopian Tube Neoplasms (18) · Breast Neoplasms (12) · Carcinoma, Ovarian Epithelial (8) · Pancreatic Neoplasms (8) · Colorectal Neoplasms (6) · Endometrial Neoplasms (6) · Lung Neoplasms (6) · Sarcoma (6) · Primary Ovarian Insufficiency (5) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Colonic Neoplasms (4) · Hyperandrogenism (4)
Female Urogenital Diseases (94) · Female Urogenital Diseases and Pregnancy Complications (94) · Genital Diseases (94) · Genital Diseases, Female (94) · Urogenital Diseases (94) · Endocrine System Diseases (89) · Gonadal Disorders (89) · Ovarian Diseases (88) · Neoplasms (84) · Neoplasms by Site (60) · Genital Neoplasms, Female (59) · Urogenital Neoplasms (59) · Endocrine Gland Neoplasms (55) · Cysts (27)
Metformin (7) · olaparib (5) · Cyclophosphamide (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · Spironolactone (4) · Aspirin (3) · Progesterone (3) · fludarabine (3) · ganirelix (3) · 1,2-diaminocyclohexaneplatinum II citrate (2) · Carboplatin (2) · Cisplatin (2) · Cosyntropin (2) · Cytoreduction Surgical Procedures (2)
University of Virginia (12) · Mayo Clinic (6) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · Cairo University (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Memorial Sloan Kettering Cancer Center (2) · OHSU Knight Cancer Institute (2) · Ohio State University Comprehensive Cancer Center (2) · Shanghai Yunying Medical Technology (2) · Shi Yun (2) · University of Oklahoma (2) · Yale University (2) · AA Secord (1) · Abramson Cancer Center at Penn Medicine (1)
United States (56) · China (15) · Egypt (4) · France (1) · Indonesia (1) · Iran (1) · Israel (1) · Italy (1) · Norway (1) · Pakistan (1) · South Korea (1) · Sweden (1) · United Kingdom (1)
Christine Burt Solorzano, MD (5) · Christine Burt Solorzano, M.D. (2) · Christine M. Burt Solorzano, MD (2) · Nina Stachenfeld, PhD (2) · Shannon N Westin (2) · Aaron Weitzman, MD (1) · Adam H Buchanan, MS, MPH, CGC (1) · Aminah Jatoi, M.D. (1) · Angeles A Secord, MD (1) · Bobbie Jo Rimel, MD (1) · Candice Jersey, D.O. (1) · Carola A. S. Arndt, MD (1)
PMID 32379297, PMID 42294856, PMID 17973110, PMID 18450135, PMID 19525452, PMID 20123766, PMID 21324454, PMID 22082029, PMID 23932181, PMID 24873996, PMID 25096410, PMID 25780518, PMID 26240596, PMID 26460999, PMID 26613820, PMID 27039941, PMID 27894428, PMID 28079776, PMID 28185689, PMID 28296829, PMID 29300925, PMID 29940135, PMID 29980460, PMID 30683761, PMID 31289908, PMID 31500875, PMID 32414353, PMID 32727709, PMID 35254001, PMID 35289396, PMID 36512649, PMID 36984856, PMID 37344887, PMID 38719544, PMID 38947323, PMID 39922106, PMID 41101974, PMID 41193187, PMID 6836800, PMID 8177055, PMID 9761364
P30CA016672 (3), P30CA015083 (2), R01HD102060 (2), 2023 (1), N01CN00034 (1), P30CA015704 (1), P30CA043703 (1), P50CA083639 (1), P50CA136393 (1), P50HD028934 (1), R01HG009671 (1), R01HL135089 (1), R21HL093450 (1), R44CA275590 (1), U01CA154967 (1)